Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT02399189 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of chemotherapy with MT-R followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma.

NCT ID: NCT02399085 Completed - Clinical trials for Diffuse Large B-cell Lymphoma

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

L-MIND
Start date: March 29, 2016
Phase: Phase 2
Study type: Interventional

This is a Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL).

NCT ID: NCT02398240 Completed - Hodgkin Lymphoma Clinical Trials

Brentuximab for Newly Diagnosed Hodgkin Disease

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).

NCT ID: NCT02396134 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Start date: May 21, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune response and may reduce cytomegalovirus events after donor stem cell transplant.

NCT ID: NCT02396043 Recruiting - Clinical trials for Lymphoma, Lymphoblastic

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.

NCT ID: NCT02395601 Completed - B-Cell Lymphoma Clinical Trials

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

Start date: March 2015
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.

NCT ID: NCT02393157 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

O-ICE
Start date: August 21, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

NCT ID: NCT02392611 Completed - Clinical trials for Solid Tumors and Lymphomas

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Start date: March 16, 2015
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or recommended dose for phase 2 study (RDP2) of alobresib as a monotherapy in participants with advanced solid tumors and lymphomas, and in combination with exemestane or fulvestrant in participants with advanced estrogen receptor positive breast cancer.

NCT ID: NCT02392039 Terminated - Lymphoma Clinical Trials

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Start date: December 14, 2015
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts).

NCT ID: NCT02391545 Terminated - Clinical trials for CD20+ Follicular Lymphoma

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.